Sagimet Biosciences (SGMT) drew fresh attention after reporting that Denifanstat met all primary and secondary endpoints with a favorable safety profile in a Phase 3 acne trial, underscoring progress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results